Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab

Silkiss, Rona Z.; Paap, Michael K; Roelofs, Kelsey A.; Agi, Jorge; Weis, Ezekiel

doi:10.1016/j.jcjo.2020.07.020

Cited by 15 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies in TED patients have used intravenous TCZ 8 mg/kg or placebo on weeks 0, 4, 8, and 12 ( 84 , 111 , 112 ). A subcutaneous preparation of TCZ is now available and requires further exploration in TED ( 113 , 114 ).…”

Section: Management Of Moderate-to-severe Tedmentioning

confidence: 99%

Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association

Burch

Perros

Bednarczuk

et al. 2022

European Thyroid Journal

View full text Add to dashboard Cite

Thyroid eye disease (TED) remains challenging for clinicians to evaluate and manage. Novel therapies have recently emerged, and their specific roles are still being determined. Most patients with TED develop eye manifestations while being treated for hyperthyroidism and under the care of endocrinologists. Endocrinologists, therefore, have a key role in diagnosis, initial management, and selection of patients who require referral to specialist care. Given that the need for guidance to endocrinologists charged with meeting the needs of patients with TED transcends national borders, and to maximize an international exchange of knowledge and practices, the American Thyroid Association and European Thyroid Association joined forces to produce this Consensus Statement.

show abstract

Section: Management Of Moderate-to-severe Tedmentioning

confidence: 99%

Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association

Burch

Perros

Bednarczuk

et al. 2022

European Thyroid Journal

View full text Add to dashboard Cite

show abstract

“…Novel treatments that are currently being explored include the use of selenium, small-molecule ligand antagonists for the TSH receptor stimulatory antibodies and the use of teprotumumab (an IGF-1 receptor blocker), tocilizumab (IL-6 receptor antagonist), and rituximab (Anti-CD20 monoclonal antibody), especially for corticosteroids resistant cases [28][29][30] .…”

Section: Treatment and Prognosismentioning

confidence: 99%

Thyroid disease and associated ophthalmopathy

Concepción¹,

Marte²,

Escalante³

2022

HGMX

View full text Add to dashboard Cite

Thyroid-associated ophthalmopathy is a complex pathology most of the time accompanying Graves' disease, also present in other thyroid states, such as Hashimoto's hypothyroidism and euthyroid states. The term Grave's disease associated ophthalmopathy can be misleading as it does not include all thyroid states associated to this eye condition. Its pathophysiology includes complex autoimmune mechanisms associated with fibroblasts, T-lymphocytes, myocytes, thyroid cells, adipocytes, and pro-inflammatory molecules, leading to several changes in the orbital content, including limitation of space, functional impairment, and complications secondary to the initial process. Reviewing its diagnostic methods and treatments is necessary due to new insights into the pathophysiology. The complexity of its pathogenesis is accompanied by a practical assessment and classification that allows clinicians to obtain significant amount of success when treating it.

show abstract

“…Prior studies have elucidated that the efficacy and safety of subcutaneous TCZ are almost congruent with intravenous administration in patients with rheumatoid arthritis [64] . Its off-label subcutaneous use has been described in several GO cases that all exhibited clinical improvement in thyroid eye disease activity [55,65,66] . Therefore, the therapy of TCZ in GO still needs further research.…”

Section: Tocilizumab (Tcz)mentioning

confidence: 99%

Pathogenesis and Targeted Biologic Therapies for Thyroid-Associated Orbitopathy: A Review

2022

FMSR

View full text Add to dashboard Cite

Purpose: To review the pathogenesis and current targeted biologic therapies of Thyroidassociated orbitopathy (TAO). Methods: Pubmed, Cochrane Library databases, Wanfang database and recent relevant journal articles were searched. Results: TAO, a potentially vision-threatening disease, is the most common extrathyroidal manifestation of Graves' Disease (GD). The complex pathogenesis of TAO involves in multiple factors, which has puzzled scientists for many years. With emerging advances in pathogenesis of TAO, novel therapeutic targets have been discovered. For example, rituximab (that acts against CD20), tocilizumab (that acts against the IL-6 receptor), teprotumumab (that blocks IGF-1R) and TNF-αinhibitors have proven to be useful and safe therapeutic options in TAO treatment. Conclusions: Targeted biological agents can provide many benefits for TAO treatments. And there is still a long way to go before the potential molecular pathogenesis and novel treatment options of GO are revealed.

show abstract

Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab

Cited by 15 publications

References 16 publications

Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association

Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association

Thyroid disease and associated ophthalmopathy

Pathogenesis and Targeted Biologic Therapies for Thyroid-Associated Orbitopathy: A Review

Contact Info

Product

Resources

About